Mobile Computing Today News from the Mobile World
The latest market report published by Acute Market Reports, Inc., the market for angina pectoris treatment was valued at USD 7.962.8 million in 2015 and is expected to reach USD 12.589.6 million by 2022, increasing to CAGR by 5.2 per cent from 2016 to 2022.
Market Insights
According to the American College of Cardiology, Chronic angina affects more than seven million North Americans and, despite optimal pharmacological and interventional therapy, 32 per cent of these patients remain symptomatic of coronary artery disease (CAD). Market experts suggest that different approaches have included new pharmacological anti-anginal agents, interventional approaches and therapeutic angiogenesis for the treatment of angina pectoris. Beta adrenergic blockers are the first-line drugs and the largest segment of the drug class in the angina pectoris market.
Browse Full Report Originally Published by Acute Market Reports at https://www.acutemarketreports.com/report/angina-pectoris-treatment-market
The key factors contributing to the growth of beta-adrenergic blockers are efficiency, rapid onset of action, patient accessibility and high patient compliance. A few drugs in phase III clinical trials have been identified as the most potential molecules in angina pectoris therapy. These potential molecules are Dantonic / T89 (Tasly Pharmaceuticals, Inc.), Bococizumab (Pfizer, Inc.) and Alirocumab (Sanofi SA, Regeneron Pharmaceuticals). North America angina pectoris treatment market is the largest market globally due to factors such as Rising prevalence of angina pectoris, obesity in young population, sedentary lifestyle, and rising awareness related to early diagnosis of angina pectoris.
Pipeline Analysis
The phase III drugs included in the pipeline analysis are Dantonic/T89 (Tasly Pharmaceuticals, Inc.), RANCAD (TSH Biopharm Corporation Limited), Cilostazol (Korea Otsuka Pharmaceutical Co.,Ltd.), Bococizumab (Pfizer, Inc.), Ticagrelor (J.M. ten Berg/ Astra Zeneca plc), Auto-CD34+ cells (Baxalta US Inc.) and Alirocumab (Sanofi SA, Regeneron Pharmaceuticals). Dantonic /T89 is observed as the most potential drug molecule in angina pectoris treatment in the near future. According to Tasly Pharmaceuticals, Inc. the study completion of phase III trial for Dantonic would be by December 2016. According to U.S. National Institutes of Health, Dantonic (T89) is a botanical drug that comprises extracts of Danshen (Radix Salviae Miltiorrhizae) and Sanqi (Radix Notoginseng) with borneol in a capsule form.
The drug is currently approved in 26 countries outside the USA for the treatment and prevention of chronic stable angina pectoris and other cardiovascular disease related conditions. This pivotal confirmative Phase III clinical trial is to confirm the efficacy and safety of the drug at 150mg and 225mg doses in the prevention and treatment of angina pectoris in patients with Chronic Stable Angina. Thus, according to its exceptional results projected in phase II suggest that Dantonic would be the most potential pipeline drug for angina pectoris treatement.
Key Market Movements:
- Rising prevalence of angina pectoris due to sedentary lifestyle and obesity in young generation
- High demand for target specific and tailored drugs for angina pectoris treatment
- In developing countries from Asia Pacific and Latin America the awareness related to cardiovascular diseases in increasing
Report Scope by Segments
By Drug Type
- Antiplatelet agents
- Beta-adrenergic blocking agents
- Calcium channel blockers
- Short & Long – acting Nitroglycerines
- Angiotensin-converting enzyme (ACE) inhibitors
- Anti-ischemic agents
By Geography Segment
- North America (U.S., Rest of North America)
- Europe (U.K., Germany, France, Rest of Europe)
- Asia Pacific (China, Japan, India, Rest of Asia Pacific)
- Rest of the World (Middle East & Africa, Latin America)
